Mitochondrial-targeting fluorescent small molecule IR-780 alleviates radiation-induced brain injury

• DOI: 10.1016/j.brainres.2023.148285
• Publication Date: 2023-02-15T16:12:36Z
• Authors: Can Zhang; Jiancheng Zheng; Wanchao Chen; Wei Yang; Xu Tan; Xiaotang Fan; Gufang Shen; Langfan Qu; Zelin Chen; Chunmeng Shi
• Keywords: 0303 health sciences; 03 medical and health sciences; Blood-Brain Barrier; Brain Injuries; Neuroinflammatory Diseases; Humans; Endothelial Cells; Brain; 3. Good health; Mitochondria

Radiation-induced brain injury (RIBI) is a common complication of radiation therapy for brain tumors. Vascular damage is one of the key factors closely related to the severity of the RIBI. However, effective vascular target treatment strategies are lacking. Previously, we have identified a fluorescent small molecule dye, IR-780, which shows the properties of injury tissue targeting and provided protection against various injuries by modulating oxidative stress. This study aims to validate the therapeutic effect of IR-780 on RIBI. The effectiveness of IR-780 against RIBI has been comprehensively evaluated through techniques such as behavior, immunofluorescence staining, quantitative real-time polymerase chain reaction, Evans Blue leakage experiments, electron microscopy, and flow cytometry. Results show that IR-780 improves cognitive dysfunction, reduces neuroinflammation, restores the expression of tight junction proteins in the blood-brain barrier (BBB), and promotes the recovery of BBB function after whole brain irradiation. IR-780 also accumulates in injured cerebral microvascular endothelial cells, and its subcellular location is in the mitochondria. More importantly, IR-780 can reduce the levels of cellular reactive oxygen species and apoptosis. Moreover, IR-780 has no significant toxic side effects. IR-780 alleviates RIBI by protecting vascular endothelial cells from oxidative stress, reducing neuroinflammation, and restoring BBB function, suggesting IR-780 as a promising treatment candidate for RIBI therapy.